Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular Degeneration

Phase 1 Completed 50 enrolled Alcon Research

Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to evaluate the safety, tolerability, and serum pharmacokinetics of CLG561 in subjects with advanced age-related macular degeneration (AMD).

Timeline

Start: 2013-05
Primary completion: 2014-11
Completion: 2014-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CLG561	Unknown	—	Intravitreal

Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular Degeneration

Summary

Timeline

Drugs

Indications